Research Frontiers and Clinical Translation

from bench to clinic

FOXO4-DRI has accumulated more than eight years of preclinical evidence since the landmark 2017 Cell paper. The path to human use is long and the obstacles are significant. This unit maps where development stands today, what Cleara Biotech is pursuing, and what the next generation of senolytic strategies might look like as the field matures.